Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/ PALB2 mutation
- Eileen M. O’Reilly*
- , Jonathan W. Lee
- , Mark Zalupski
- , Marinela Capanu
- , Jennifer Park
- , Talia Golan
- , Esther Tahover
- , Maeve A. Lowery
- , Joanne F. Chou
- , Vaibhav Sahai
- , Robin Brenner
- , Hedy L. Kindler
- , Kenneth H. Yu
- , Alice Zervoudakis
- , Shreya Vemuri
- , Zsofia K. Stadler
- , Richard K.G. Do
- , Neesha Dhani
- , Alice P. Chen
- , David P. Kelsen
*Corresponding author for this work
- Memorial Sloan-Kettering Cancer Center
- University of Michigan, Ann Arbor
- Sheba Medical Center at Tel Hashomer
- Shaare Zedek Medical Center
- Trinity College Dublin
- The University of Chicago
- Princess Margaret Hospital
- National Institutes of Health
Research output: Contribution to journal › Article › peer-review
380
Scopus
citations